At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,892 enrolled
Drug / intervention
EVO100 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
In Brief
A Phase 3 clinical trial evaluating EVO100 and Placebo for Sexually Transmitted Diseases and 2 related conditions. Completed, enrolled 1,892 participants across 98 sites.
Detailed Summary
This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexually Transmitted Diseases, Gonorrhea, Chlamydia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionJul 2022
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartOct 15, 2020
Primary CompletionJul 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.8 years ago
Interventions
EVO100drug
EVO100 vaginal gel
Placebodrug
Placebo vaginal gel